Lincoln Medical Center, New York, NY.
Department of Medicine, Division of Cardiology, Boonshoft School of Medicine, Wright State University.
Curr Probl Cardiol. 2023 Jul;48(7):101686. doi: 10.1016/j.cpcardiol.2023.101686. Epub 2023 Mar 8.
Hypertension is one of the most common disorders encountered, yet pharmacotherapy for resistant hypertension has limited effective options. Aprocitentan is postulated to be a novel antihypertensive. The main goal was to determine the effect of aprocitentan on blood pressure among patients with hypertension. A thorough search of 5 electronic databases, including PubMed Central, PubMed, EMBASE, Springer, and Google Scholar, was carried out. The study included eight articles. With doses exceeding 25 mg, plasma ET-1(endothelin-1) concentrations, which show ETB (Endothelin receptor type B) receptor antagonism, significantly rose. Aprocitentan significantly reduced systolic and diastolic blood pressure with both doses of 10mg and 25mg in patients with hypertension. Further research is warranted to evaluate the efficacy, safety, and long-term outcomes of aprocitentan and its synergistic effect with other antihypertensives.
高血压是最常见的疾病之一，然而，治疗耐药性高血压的药物治疗选择有限。Aprocitentan 被认为是一种新型的降压药。主要目的是确定 aprocitentan 对高血压患者血压的影响。对包括 PubMed Central、PubMed、EMBASE、Springer 和 Google Scholar 在内的 5 个电子数据库进行了全面搜索。该研究包括 8 篇文章。超过 25 毫克的剂量时，表现出 ETB（内皮素受体 B 型）受体拮抗作用的血浆 ET-1（内皮素-1）浓度显著升高。Aprocitentan 显著降低了高血压患者的收缩压和舒张压，两种剂量（10mg 和 25mg）都有效。需要进一步研究来评估 aprocitentan 的疗效、安全性和长期结果及其与其他降压药的协同作用。
